244 related articles for article (PubMed ID: 30849944)
21. Breastfeeding, PAM50 tumor subtype, and breast cancer prognosis and survival.
Kwan ML; Bernard PS; Kroenke CH; Factor RE; Habel LA; Weltzien EK; Castillo A; Gunderson EP; Maxfield KS; Stijleman IJ; Langholz BM; Quesenberry CP; Kushi LH; Sweeney C; Caan BJ
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25921910
[TBL] [Abstract][Full Text] [Related]
22. Immune gene expression profiling reveals heterogeneity in luminal breast tumors.
Zhu B; Tse LA; Wang D; Koka H; Zhang T; Abubakar M; Lee P; Wang F; Wu C; Tsang KH; Chan WC; Law SH; Li M; Li W; Wu S; Liu Z; Huang B; Zhang H; Tang E; Kan Z; Lee S; Park YH; Nam SJ; Wang M; Sun X; Jones K; Zhu B; Hutchinson A; Hicks B; Prokunina-Olsson L; Shi J; Garcia-Closas M; Chanock S; Yang XR
Breast Cancer Res; 2019 Dec; 21(1):147. PubMed ID: 31856876
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.
Schroth W; Winter S; Büttner F; Goletz S; Faißt S; Brinkmann F; Saladores P; Heidemann E; Ott G; Gerteis A; Alscher MD; Dippon J; Schwab M; Brauch H; Fritz P
Breast Cancer Res Treat; 2016 Jan; 155(1):85-97. PubMed ID: 26650824
[TBL] [Abstract][Full Text] [Related]
24. Nuclear PDCD4 Expression Defines a Subset of Luminal B-Like Breast Cancers with Good Prognosis.
Madera S; Chervo MF; Chiauzzi VA; Pereyra MG; Venturutti L; Izzo F; Roldán Deamicis A; Guzman P; Dupont A; Roa JC; Cenciarini ME; Barchuk S; Figurelli S; Lopez Della Vecchia D; Levit C; Lebersztein G; Anfuso F; Castiglioni T; Cortese E; Ares S; Deza EG; Gercovich FG; Proietti CJ; Schillaci R; Cordo Russo RI; Elizalde PV
Horm Cancer; 2020 Oct; 11(5-6):218-239. PubMed ID: 32632815
[TBL] [Abstract][Full Text] [Related]
25. Research-based PAM50 signature and long-term breast cancer survival.
Pu M; Messer K; Davies SR; Vickery TL; Pittman E; Parker BA; Ellis MJ; Flatt SW; Marinac CR; Nelson SH; Mardis ER; Pierce JP; Natarajan L
Breast Cancer Res Treat; 2020 Jan; 179(1):197-206. PubMed ID: 31542876
[TBL] [Abstract][Full Text] [Related]
26. PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer.
Ohara AM; Naoi Y; Shimazu K; Kagara N; Shimoda M; Tanei T; Miyake T; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2019 Feb; 173(3):533-543. PubMed ID: 30361874
[TBL] [Abstract][Full Text] [Related]
27. Frequent Molecular Subtype Switching and Gene Expression Alterations in Lung and Pleural Metastasis From Luminal A-Type Breast Cancer.
Klebe M; Fremd C; Kriegsmann M; Kriegsmann K; Albrecht T; Thewes V; Kirchner M; Charoentong P; Volk N; Haag J; Wirtz R; Oskarsson T; Schulz A; Heil J; Schneeweiss A; Winter H; Sinn P
JCO Precis Oncol; 2020; 4():. PubMed ID: 32923902
[TBL] [Abstract][Full Text] [Related]
28. Basal biomarkers nestin and INPP4b identify intrinsic subtypes accurately in breast cancers that are weakly positive for oestrogen receptor.
Asleh-Aburaya K; Sheffield BS; Kos Z; Won JR; Wang XQ; Gao D; Wolber R; Gilks CB; Bernard PS; Chia SK; Nielsen TO
Histopathology; 2017 Jan; 70(2):185-194. PubMed ID: 27402148
[TBL] [Abstract][Full Text] [Related]
29. Race and breast cancer survival by intrinsic subtype based on PAM50 gene expression.
Kroenke CH; Sweeney C; Kwan ML; Quesenberry CP; Weltzien EK; Habel LA; Castillo A; Bernard PS; Factor RE; Kushi LH; Caan BJ
Breast Cancer Res Treat; 2014 Apr; 144(3):689-99. PubMed ID: 24604094
[TBL] [Abstract][Full Text] [Related]
30. Breast carcinoma subtypes show different patterns of metastatic behavior.
Molnár IA; Molnár BÁ; Vízkeleti L; Fekete K; Tamás J; Deák P; Szundi C; Székely B; Moldvay J; Vári-Kakas S; Szász MA; Ács B; Kulka J; Tőkés AM
Virchows Arch; 2017 Mar; 470(3):275-283. PubMed ID: 28101678
[TBL] [Abstract][Full Text] [Related]
31. Association of high obesity with PAM50 breast cancer intrinsic subtypes and gene expression.
Kwan ML; Kroenke CH; Sweeney C; Bernard PS; Weltzien EK; Castillo A; Factor RE; Maxfield KS; Stijleman IJ; Kushi LH; Quesenberry CP; Habel LA; Caan BJ
BMC Cancer; 2015 Apr; 15():278. PubMed ID: 25884832
[TBL] [Abstract][Full Text] [Related]
32. PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients-a South African cohort study.
Phakathi B; Dix-Peek T; Van Den Berg E; Dickens C; Nietz S; Cubasch H; Joffe M; Neugut AI; Jacobson JS; Ruff P; Duarte R
Breast Cancer Res Treat; 2023 Aug; 200(3):337-346. PubMed ID: 37266756
[TBL] [Abstract][Full Text] [Related]
33. TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance.
Silwal-Pandit L; Vollan HK; Chin SF; Rueda OM; McKinney S; Osako T; Quigley DA; Kristensen VN; Aparicio S; Børresen-Dale AL; Caldas C; Langerød A
Clin Cancer Res; 2014 Jul; 20(13):3569-80. PubMed ID: 24803582
[TBL] [Abstract][Full Text] [Related]
34. Gene modules associated with breast cancer distant metastasis-free survival in the PAM50 molecular subtypes.
Liu R; Zhang W; Liu ZQ; Zhou HH
Oncotarget; 2016 Apr; 7(16):21686-98. PubMed ID: 26934123
[TBL] [Abstract][Full Text] [Related]
35. Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response.
Magbanua MJ; Wolf DM; Yau C; Davis SE; Crothers J; Au A; Haqq CM; Livasy C; Rugo HS; ; Esserman L; Park JW; van 't Veer LJ
Breast Cancer Res; 2015 May; 17(1):73. PubMed ID: 26021444
[TBL] [Abstract][Full Text] [Related]
36. Prediction consistency and clinical presentations of breast cancer molecular subtypes for Han Chinese population.
Huang CC; Tu SH; Lien HH; Jeng JY; Liu JS; Huang CS; Wu YY; Liu CY; Lai LC; Chuang EY
J Transl Med; 2012 Sep; 10 Suppl 1(Suppl 1):S10. PubMed ID: 23046482
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of invasive breast cancer samples using a 12-chemokine gene expression score: correlation with clinical outcomes.
Prabhakaran S; Rizk VT; Ma Z; Cheng CH; Berglund AE; Coppola D; Khalil F; Mulé JJ; Soliman HH
Breast Cancer Res; 2017 Jun; 19(1):71. PubMed ID: 28629479
[TBL] [Abstract][Full Text] [Related]
38. Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series.
Picornell AC; Echavarria I; Alvarez E; López-Tarruella S; Jerez Y; Hoadley K; Parker JS; Del Monte-Millán M; Ramos-Medina R; Gayarre J; Ocaña I; Cebollero M; Massarrah T; Moreno F; García Saenz JA; Gómez Moreno H; Ballesteros A; Ruiz Borrego M; Perou CM; Martin M
BMC Genomics; 2019 Jun; 20(1):452. PubMed ID: 31159741
[TBL] [Abstract][Full Text] [Related]
39. PCA-PAM50 improves consistency between breast cancer intrinsic and clinical subtyping reclassifying a subset of luminal A tumors as luminal B.
Raj-Kumar PK; Liu J; Hooke JA; Kovatich AJ; Kvecher L; Shriver CD; Hu H
Sci Rep; 2019 May; 9(1):7956. PubMed ID: 31138829
[TBL] [Abstract][Full Text] [Related]
40. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.
Jézéquel P; Loussouarn D; Guérin-Charbonnel C; Campion L; Vanier A; Gouraud W; Lasla H; Guette C; Valo I; Verrièle V; Campone M
Breast Cancer Res; 2015 Mar; 17():43. PubMed ID: 25887482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
